<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3377">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394692</url>
  </required_header>
  <id_info>
    <org_study_id>JWG-EK 239/07</org_study_id>
    <nct_id>NCT01394692</nct_id>
  </id_info>
  <brief_title>Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery</brief_title>
  <official_title>Resection Control of Primary Brain Tumours Using a Low-Field Intraoperative MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goethe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goethe University</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excision to the maximum possible extent marks the first step of glioma surgery. Depending on
      tumour histology, adjuvant treatment consists of radio- and/or chemotherapy. Multi-centre
      studies have shown that the presence of residual tumour according to MRI-criteria is a
      prognostic factor in this incurable condition.

      In order to improve the extent of resection, several methods, in particular intraoperative
      imaging techniques, have become available to demonstrate already during surgery whether the
      goal of surgery has been achieved. The intraoperative MRI devices currently available differ
      in their magnetic field strengths and image resolution, but also in their amount of
      interference with the surgical workflow.

      Prospective, high-class evidence data to promote the use of intraoperative MRI in glioma
      surgery are lacking. To assess whether the rate of radiologically complete tumour resections
      can be improved by using intraoperative MRI-guidance, we designed this prospective,
      randomized trial. We hypothesized that the extent of resection that can be achieved using an
      intraoperative MRI is greater than that of conventional microsurgical tumor resection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Extent of Resection</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with contrast-enhancing glioma in whom a complete excision of the tumor according to postoperative high-field MRI within 72 hours is achieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (radiological and/or clinical progression) at 6 months following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric Assessment</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Volumetric assessment of the extent of resection on early (within 72h) postoperative MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Deficit</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of new postoperative deficits following tumor surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>intraoperative MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tumor resection with intraoperative MRI-guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard microsurgical tumor resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intraoperative MRI-guided tumor resection</intervention_name>
    <description>tumor resection with the use of an intraoperative MRI</description>
    <arm_group_label>intraoperative MRI</arm_group_label>
    <other_name>PoleStar-N20 intraoperative MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard microsurgery</intervention_name>
    <description>microsurgical tumor resection</description>
    <arm_group_label>conventional group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  known or suspected contrast-enhancing glioma (primary and recurrent)

          -  location of the tumor permits intended gross-total resection

        Exclusion Criteria:

          -  tumor location prohibits or questions gross-total resection

          -  contraindications to undergo MRI examinations
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Senft, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker Seifert, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurosurgery, Goethe-University</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011 Oct;12(11):997-1003. doi: 10.1016/S1470-2045(11)70196-6. Epub 2011 Aug 23.</citation>
    <PMID>21868284</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 29, 2012</lastchanged_date>
  <firstreceived_date>July 13, 2011</firstreceived_date>
  <firstreceived_results_date>September 20, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Goethe University</investigator_affiliation>
    <investigator_full_name>Christian Senft</investigator_full_name>
    <investigator_title>Neurosurgeon</investigator_title>
  </responsible_party>
  <keyword>intraoperative MRI</keyword>
  <keyword>glioma surgery</keyword>
  <keyword>extent of resection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intraoperative MRI</title>
          <description>tumor resection with intraoperative MRI-guidance</description>
        </group>
        <group group_id="P2">
          <title>Conventional Group</title>
          <description>standard microsurgical tumor resection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intraoperative MRI</title>
          <description>tumor resection with intraoperative MRI-guidance</description>
        </group>
        <group group_id="B2">
          <title>Conventional Group</title>
          <description>standard microsurgical tumor resection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57" spread="13"/>
                <measurement group_id="B2" value="58" spread="13"/>
                <measurement group_id="B3" value="58" spread="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Extent of Resection</title>
        <description>Number of patients with contrast-enhancing glioma in whom a complete excision of the tumor according to postoperative high-field MRI within 72 hours is achieved</description>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients in whom histological examination of tumor specimens did not result in diagnosis of a glioma were excluded for final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative MRI</title>
            <description>tumor resection with intraoperative MRI-guidance</description>
          </group>
          <group group_id="O2">
            <title>Conventional Group</title>
            <description>standard microsurgical tumor resection</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Extent of Resection</title>
            <description>Number of patients with contrast-enhancing glioma in whom a complete excision of the tumor according to postoperative high-field MRI within 72 hours is achieved</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival (radiological and/or clinical progression) at 6 months following surgery</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volumetric Assessment</title>
        <description>Volumetric assessment of the extent of resection on early (within 72h) postoperative MRI</description>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurological Deficit</title>
        <description>Assessment of new postoperative deficits following tumor surgery</description>
        <time_frame>7 days</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intraoperative MRI</title>
          <description>tumor resection with intraoperative MRI-guidance</description>
        </group>
        <group group_id="E2">
          <title>Conventional Group</title>
          <description>standard microsurgical tumor resection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christian Senft</name_or_title>
      <organization>Johann Wolfgang Goethe University</organization>
      <phone>+49 69 63015939</phone>
      <email>c.senft@med.uni-frankfurt.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
